Hormonal
Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major renal events, cardiovascular death, and all-cause death in patients with type 2 diabetes and chronic kidney disease.
If you have type 2 diabetes and chronic kidney disease, ask your doctor about weekly semaglutide injections. This treatment has been shown to significantly slow the progression of kidney disease and reduce the risk of heart-related death and overall death, offering strong protection for your kidneys and heart.
The primary renal endpoints were reduced by 24% (hazard ratio 0.76, 95% confidence interval 0.66-0.88). The cardiovascular death and all-cause death were also significantly reduced (hazard ratio 0.71, 95% confidence interval 0.56-0.89; hazard ratio 0.80, 95% confidence interval 0.67-0.95).
Why this rating
Based on the FLOW trial, a large-scale randomized clinical trial.
Source
Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health
Chern-En Chiang et al. · Journal of the Chinese Medical Association · 2025
DOI 10.1097/jcma.0000000000001263
More from this paper
- Weekly subcutaneous semaglutide (1.0 mg) significantly reduces major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.Strong
- Weekly subcutaneous semaglutide (2.4 mg) significantly reduces body weight and major adverse cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.Strong
- Weekly subcutaneous semaglutide (2.4 mg) significantly improves functional capacity and reduces heart failure hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →